

## Expected major R&D *milestones* in 2024

		<i>H1 2024</i>	<i>H2 2024</i>
<b>Dupixent</b>	COPD		U.S./EU Approval
	CSU (Study C)		Pivotal trial readout
<b>tolebrutinib</b>	RMS (GEMINI 1/2)		Pivotal trial readout
	nrSPMS (HERCULES)		Pivotal trial readout
<b>amlitelimab</b>	Asthma		Phase 2 readout
<b>rilzabrutinib</b>	ITP (LUNA 3)	Pivotal trial readout	
	Asthma	Phase 2 readout (HD)	
<b>Sarclisa</b>	1L MM Ti (IMROZ)	U.S. Submission	
	SubQ 2/3L MM (IRAKLIA)		Pivotal trial readout